Targeted therapies with chemoradiation in esophageal cancer: development and future directions

Area of Science:

• Oncology
• Gastroenterology
• Pharmacology

Background:

• Targeted therapies are being investigated alongside chemoradiation for esophageal and gastroesophageal junction cancers.
• Human Epidermal Growth Factor Receptor 2 (HER2), epidermal growth factor receptor, and vascular endothelial growth factor pathways have been the primary focus in esophagogastric cancers.
• Despite promising preclinical data, the efficacy of these targeted agents has been inconsistent in metastatic settings or combined with chemoradiation.

Purpose of the Study:

• To review the historical development of targeted therapies in esophagogastric cancers.
• To focus on the integration of targeted agents with chemoradiation.
• To discuss novel targets such as c-MET, heat shock protein 90, and Sonic hedgehog in the context of chemoradiation.

Main Methods:

• Literature review of targeted therapies in esophagogastric cancers.
• Analysis of studies combining targeted agents with chemoradiation.
• Discussion of emerging molecular targets and their potential role in treatment.

Main Results:

• Extensive research has focused on HER2, EGFR, and VEGF pathways with varied outcomes.
• Previous targeted therapies have shown mixed efficacy when combined with chemoradiation or in metastatic disease.
• Emerging targets like c-MET, HSP90, and Sonic hedgehog present new avenues for investigation.

Conclusions:

• The development of targeted therapies for esophagogastric cancers, particularly with chemoradiation, requires further refinement.
• Understanding the historical context and exploring novel targets are crucial for advancing treatment efficacy.
• Future research should focus on integrating newer targeted agents with chemoradiation to overcome current limitations.